The practice must have at least one study utilizing some form of control (e.g., untreated group, placebo group, matched wait list study) establishing the practice's
benefit over the placebo, or found it to be comparable to or better than an appropriate comparison practice.
As for Kirsch's research, Kramer believes the conclusion antidepressants provide little
benefit over placebo is «implausible».
Earlier research has already demonstrated paracetamol is ineffective and opioids provide minimal
benefit over placebo.
Nearly half of the studies (eight of the acute and one of the chronic pain) suggested that antidepressants resulted in significant treatment
benefits over placebo.
Not exact matches
The study was not powered to demonstrate a treatment effect on kidney function, but there was no evidence of a
benefit associated with bosutinib compared with
placebo over the 2 - year treatment period.
The study failed to meet both of its co-primary endpoints in that it did not show a significant
benefit of steroid treatment
over placebo in terms of either the overall rate of death or a composite metric that included death, heart attack, stroke, new renal failure or respiratory failure.
Two new phase III clinical trials investigating the efficacy and safety of bitopertin, a glycine uptake inhibitor considered to be a promising new add - on therapy for treating negative symptoms in schizophrenia, failed to show a
benefit of the drug
over placebo.
With regard to pharmacological options for the treatment chronic irritability, the only randomised controlled trial in children with SMD found no
benefit of lithium
over placebo.